<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966576</url>
  </required_header>
  <id_info>
    <org_study_id>SMA-08-22a</org_study_id>
    <nct_id>NCT00966576</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Adding Azarga to Prostaglandin Monotherapy</brief_title>
  <official_title>The Efficacy and Safety of Adding the Brinzolamide/Timolol Maleate Fixed Combination (AzargaÂ®) to Prostaglandin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of adding AZARGA in glaucoma&#xD;
      patients with uncontrolled intraocular pressure (IOP), currently on prostaglandin&#xD;
      monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean decrease in intraocular pressure (IOP) at 12 weeks from baseline</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as determined by visual acuity, biomicroscopy, adverse events, solicited symptom survey and treatment success</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Brinzolamide/Timolol Maleate Fixed Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)</intervention_name>
    <description>1 drop of study medication into the study eye(s) beginning the evening of Visit 1 and continuing twice daily (morning and evening) for 12 weeks</description>
    <arm_group_label>Brinzolamide/Timolol Maleate Fixed Combination</arm_group_label>
    <other_name>AZARGA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sign Informed Consent.&#xD;
&#xD;
          -  21 years of age or older.&#xD;
&#xD;
          -  Able to follow instructions and willing to attend required study visits.&#xD;
&#xD;
          -  Clinical diagnosis of ocular hypertension, primary open-angle, or pigment dispersion&#xD;
             glaucoma in at least one eye (qualifying eye).&#xD;
&#xD;
          -  Intra-ocular pressure (IOP) considered to be safe in both eyes in such a way that&#xD;
             should assure clinical stability of vision and the optic nerve throughout the trial.&#xD;
&#xD;
          -  Must have best corrected visual acuity of 6/60 (6/60 Snellen, 1.0 LogMAR) or better in&#xD;
             each eye.&#xD;
&#xD;
          -  Other protocol-defined inclusion criteria may apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of other primary or secondary glaucomas not listed in inclusion criterion.&#xD;
&#xD;
          -  Presence of corneal dystrophies.&#xD;
&#xD;
          -  Concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either&#xD;
             eye.&#xD;
&#xD;
          -  Intraocular conventional surgery or laser surgery in qualifying eye(s) less than three&#xD;
             months prior to Visit 1.&#xD;
&#xD;
          -  Risk of visual field or visual acuity worsening as a consequence of participation in&#xD;
             the trial, in the investigator's best judgment.&#xD;
&#xD;
          -  Women of childbearing potential not using reliable means of birth control.&#xD;
&#xD;
          -  Women who are pregnant or lactating.&#xD;
&#xD;
          -  Participation in any other investigational study within 30 days prior to Visit 1.&#xD;
&#xD;
          -  Current or anticipated use of systemic corticosteroids, by any route except inhaled,&#xD;
             for greater than two weeks during the trial.&#xD;
&#xD;
          -  Severe allergic rhinitis&#xD;
&#xD;
          -  History of ocular herpes simplex.&#xD;
&#xD;
          -  Other protocol-defined exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Lorenz K, Rosbach K, Matt A, Pfeiffer N. Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension. Clin Ophthalmol. 2011;5:1745-50. doi: 10.2147/OPTH.S25987. Epub 2011 Dec 9.</citation>
    <PMID>22205835</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>August 26, 2009</study_first_submitted>
  <study_first_submitted_qc>August 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2009</study_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>IOP</keyword>
  <keyword>AZARGA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

